Hematology and Pathology Devices; Reclassification of Immunohistochemistry Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product
The Food and Drug Administration (FDA) is proposing to reclassify immunohistochemistry (IHC) test systems indicated for use with a corresponding approved oncology therapeutic product (product codes MVC, NKF, QQT, NQF, PLS, PKW, QUL, QNH, QZJ, SBL, SER, and SHF), which are postamendments class III devices, from class III (premarket approval) into class II (special controls), subject to premarket notification. FDA is proposing minor revisions to an existing classification regulation and also proposing a new device classification regulation, along with the special controls that FDA believes are necessary to provide a reasonable assurance of safety and effectiveness for these devices.
- quotes — Hematology and Pathology Devices; Reclassification of Immunohistochemistry Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product (witness: https://www.federalregister.gov; method: quoted collector metadata from an original HTTP response; citation: https://www.federalregister.gov/documents/2026/11/12/2026-23005/hematology-and-pathology-devices-reclassification-of-immunohistochemistry-test-systems-for-use-with; status: unverified)
- quotes — summary: The Food and Drug Administration (FDA) is proposing to reclassify immunohistochemistry (IHC) test systems indicated for use with a corresponding approved oncology therapeutic product (product codes MVC, NKF, QQT, NQF, PLS, PKW, QUL, QNH, QZJ, SBL, SER, and SHF), which are postamendments class III devices, from class III (premarket approval) into class II (special controls), subject to premarket notification. FDA is proposing minor revisions to an existing classification regulation and also proposing a new device classification regulation, along with the special controls that FDA believes are necessary to provide a reasonable assurance of safety and effectiveness for these devices. (witness: https://www.federalregister.gov; method: quoted collector metadata from an original HTTP response; citation: https://www.federalregister.gov/documents/2026/11/12/2026-23005/hematology-and-pathology-devices-reclassification-of-immunohistochemistry-test-systems-for-use-with; status: unverified)
- quotes — url: https://www.federalregister.gov/documents/2026/11/12/2026-23005/hematology-and-pathology-devices-reclassification-of-immunohistochemistry-test-systems-for-use-with (witness: https://www.federalregister.gov; method: quoted collector metadata from an original HTTP response; citation: https://www.federalregister.gov/documents/2026/11/12/2026-23005/hematology-and-pathology-devices-reclassification-of-immunohistochemistry-test-systems-for-use-with; status: unverified)
- quotes — source-subject: federal-register:2026-23005 (witness: https://www.federalregister.gov; method: quoted collector metadata from an original HTTP response; citation: https://www.federalregister.gov/documents/2026/11/12/2026-23005/hematology-and-pathology-devices-reclassification-of-immunohistochemistry-test-systems-for-use-with; status: unverified)
- quotes — source-edition: ni:///sha-256;QOPdJ2fJqL_VW0hQ-aNWiIfuptgqfuVWXmAOJdh1uNs (witness: https://www.federalregister.gov; method: quoted collector metadata from an original HTTP response; citation: https://www.federalregister.gov/documents/2026/11/12/2026-23005/hematology-and-pathology-devices-reclassification-of-immunohistochemistry-test-systems-for-use-with; status: unverified)
- quotes — source-metadata: {"subject":"federal-register:2026-23005","revision":"ni:///sha-256;QOPdJ2fJqL_VW0hQ-aNWiIfuptgqfuVWXmAOJdh1uNs","documentNumber":"2026-23005","documentUrl":"https://www.federalregister.gov/documents/2026/11/12/2026-23005/hematology-and-pathology-devices-reclassification-of-immunohistochemistry-test-systems-for-use-with","title":"Hematology and Pathology Devices; Reclassification of Immunohistochemistry Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product","documentType":"Proposed Rule","publicationDate":"2026-11-12","publicationDatePrecision":"civil-day","agencies":["Food and Drug Administration","Health and Human Services Department"],"abstract":"The Food and Drug Administration (FDA) is proposing to reclassify immunohistochemistry (IHC) test systems indicated for use with a corresponding approved oncology therapeutic product (product codes MVC, NKF, QQT, NQF, PLS, PKW, QUL, QNH, QZJ, SBL, SER, and SHF), which are postamendments class III devices, from class III (premarket approval) into class II (special controls), subject to premarket notification. FDA is proposing minor revisions to an existing classification regulation and also proposing a new device classification regulation, along with the special controls that FDA believes are necessary to provide a reasonable assurance of safety and effectiveness for these devices.","commentsCloseOn":"2027-01-11","commentDeadlineFieldRequested":true,"effectiveOn":null,"sourceAction":"Proposed amendment; proposed order; request for comments.","federalRegisterCitation":"91 FR 72825","docketIds":["Docket No. FDA-2026-N-12508"],"regulationIdNumbers":[],"cfrReferences":[{"chapter":null,"citation_url":null,"part":"864","title":21}],"correctionOf":null,"corrections":[],"source":{"originalApiUrl":"https://www.federalregister.gov/api/v1/documents.json?conditions%5Bpublication_date%5D%5Bgte%5D=2026-11-05&conditions%5Bpublication_date%5D%5Blte%5D=2026-11-12&per_page=100&page=1&order=newest&fields%5B%5D=document_number&fields%5B%5D=title&fields%5B%5D=type&fields%5B%5D=abstract&fields%5B%5D=html_url&fields%5B%5D=publication_date&fields%5B%5D=agencies&fields%5B%5D=comments_close_on&fields%5B%5D=effective_on&fields%5B%5D=action&fields%5B%5D=citation&fields%5B%5D=regulation_id_numbers&fields%5B%5D=cfr_references&fields%5B%5D=docket_ids&fields%5B%5D=correction_of&fields%5B%5D=corrections","originalResponseDigest":"sha256:e095feb5b9c8968c45f113720e63c822ba7fbb3afdfec0696bae46bdc204f9ef","originalResponseUri":"ni:///sha-256;4JX-tbnIloxF8RNyDmPIIrp_uzr9_sBpa65GvcIE-e8","normalizedLotDigest":"sha256:d3ff8e93b6fed45c9386d3c7086e789c7bc9c64bff674c189560c92a5daaf952","observedAt":"2026-11-12T21:30:47.088Z","provider":"https://www.federalregister.gov","publisher":{"name":"Office of the Federal Register","source":"https://www.federalregister.gov/reader-aids/developer-resources/rest-api","reproduction":"https://www.archives.gov/federal-register/faqs","officialNotice":"The source Federal Register edition, not this derived JSON, is authoritative. No government endorsement."},"evidenceClass":"source-dated government metadata, independently replayable from original HTTP bytes held by the source acquisition run"}} (witness: https://www.federalregister.gov; method: quoted collector metadata from an original HTTP response; citation: https://www.federalregister.gov/documents/2026/11/12/2026-23005/hematology-and-pathology-devices-reclassification-of-immunohistochemistry-test-systems-for-use-with; status: unverified)
- quotes — editorial-standing: source metadata; editorial acceptance pending (witness: https://www.federalregister.gov; method: quoted collector metadata from an original HTTP response; citation: https://www.federalregister.gov/documents/2026/11/12/2026-23005/hematology-and-pathology-devices-reclassification-of-immunohistochemistry-test-systems-for-use-with; status: unverified)